Johnson & Johnson fortifies urologic oncology pipeline with compelling Inlexzo results
Johnson & Johnson's new data show Inlexzo delivers strong one-year disease-free survival. Find out how it could shift bladder cancer care.
What KT‑621 success could mean for oral immunology drugs and Kymera Therapeutics
Get ready for Kymera Therapeutics' KT‑621 Phase 1b data on December 8. Can this oral eczema drug change the future of immunology?
Can Christine Nelson’s promotion as CFO bring stability to NowVertical’s roadmap?
NowVertical promotes Christine Nelson to permanent CFO, signaling financial stability and capital market alignment. Find out what it means for investors.
Can Hugo give hospitals a smarter surgical robot? FDA clearance puts Medtronic to test
Medtronic gets U.S. FDA clearance for Hugo RAS system in urologic surgery, unlocking new competition in robotic-assisted soft-tissue procedures. Read more.
What Andrew C. Schmidt’s CFO appointment means for Aviat Networks’ public safety ambitions
Aviat Networks names Andrew C. Schmidt as CFO to lead software and public safety strategy. Read what this shift means for growth, strategy, and AVNW stock.
Why some investors are uneasy about Life360’s pivot to advertising with Nativo deal
Life360 acquires Nativo for $120M to launch a family-safe, privacy-aware ad platform. Find out what this means for the future of app monetisation.
Is Snowflake’s Claude partnership the most secure AI play for regulated industries?
Snowflake deepens Claude AI partnership with Anthropic in a $200 million deal. Learn how this move reshapes enterprise AI and what it means for investors.
Inside Vodacom’s $2.1bn bet on Safaricom: Deeper control, bigger risks, and fintech ambition
Vodacom is consolidating control of Safaricom in a $2.1B deal with Kenya and Vodafone. Find out what this means for telecom, fintech, and regional strategy.
From tissue to biologic: AVANCE’s FDA clearance marks a turning point for nerve injury treatment
Axogen gets FDA biologics nod for AVANCE nerve graft, unlocking 12 years of exclusivity. Find out how this reshapes nerve repair in 2026 and beyond.
Can Cal-Maine’s $15m investment make Echo Lake a prepared foods powerhouse?
Cal-Maine Foods is investing $15 million to expand Echo Lake scrambled egg output. Learn how this fits into its high-protein convenience foods strategy.